Compare Glenmark Pharma with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs ORCHID PHARMA LTD - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA ORCHID PHARMA LTD GLENMARK PHARMA/
ORCHID PHARMA LTD
 
P/E (TTM) x 10.0 -0.5 - View Chart
P/BV x 1.4 0.1 1,218.2% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 GLENMARK PHARMA   ORCHID PHARMA LTD
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
ORCHID PHARMA LTD
Sep-13
GLENMARK PHARMA/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs712194 366.8%   
Low Rs48435 1,381.7%   
Sales per share (Unadj.) Rs349.6276.5 126.5%  
Earnings per share (Unadj.) Rs32.8-79.2 -41.4%  
Cash flow per share (Unadj.) Rs44.3-43.5 -102.0%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs198.653.9 368.3%  
Shares outstanding (eoy) m282.1770.45 400.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.70.4 412.7%   
Avg P/E ratio x18.2-1.4 -1,261.1%  
P/CF ratio (eoy) x13.5-2.6 -511.6%  
Price / Book Value ratio x3.02.1 141.7%  
Dividend payout %6.10-   
Avg Mkt Cap Rs m168,6258,067 2,090.4%   
No. of employees `00012.02.8 429.9%   
Total wages/salary Rs m20,5612,527 813.6%   
Avg. sales/employee Rs Th8,196.06,956.1 117.8%   
Avg. wages/employee Rs Th1,708.1902.5 189.3%   
Avg. net profit/employee Rs Th768.5-1,993.0 -38.6%   
INCOME DATA
Net Sales Rs m98,65519,477 506.5%  
Other income Rs m2,081407 511.1%   
Total revenues Rs m100,73619,884 506.6%   
Gross profit Rs m15,8581,103 1,438.2%  
Depreciation Rs m3,2592,519 129.4%   
Interest Rs m3,3465,227 64.0%   
Profit before tax Rs m11,335-6,236 -181.8%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,672511 327.2%   
Tax Rs m3,756-125 -3,000.3%   
Profit after tax Rs m9,250-5,580 -165.8%  
Gross profit margin %16.15.7 283.9%  
Effective tax rate %33.12.0 1,650.8%   
Net profit margin %9.4-28.7 -32.7%  
BALANCE SHEET DATA
Current assets Rs m66,96811,014 608.0%   
Current liabilities Rs m40,21132,060 125.4%   
Net working cap to sales %27.1-108.1 -25.1%  
Current ratio x1.70.3 484.8%  
Inventory Days Days8395 87.8%  
Debtors Days Days8134 242.0%  
Net fixed assets Rs m33,32229,440 113.2%   
Share capital Rs m282705 40.1%   
"Free" reserves Rs m55,7702,043 2,730.3%   
Net worth Rs m56,0523,800 1,475.1%   
Long term debt Rs m35,7389,018 396.3%   
Total assets Rs m132,88846,510 285.7%  
Interest coverage x4.4-0.2 -2,271.9%   
Debt to equity ratio x0.62.4 26.9%  
Sales to assets ratio x0.70.4 177.3%   
Return on assets %9.5-0.8 -1,247.1%  
Return on equity %16.5-146.9 -11.2%  
Return on capital %17.8-3.7 -477.0%  
Exports to sales %037.9 0.0%   
Imports to sales %022.6 0.0%   
Exports (fob) Rs mNA7,378 0.0%   
Imports (cif) Rs mNA4,406 0.0%   
Fx inflow Rs m62,9987,513 838.5%   
Fx outflow Rs m22,8595,649 404.7%   
Net fx Rs m40,1401,865 2,152.8%   
CASH FLOW
From Operations Rs m13,2421,682 787.4%  
From Investments Rs m-6,990-9,860 70.9%  
From Financial Activity Rs m-7,3876,644 -111.2%  
Net Cashflow Rs m-2,971-1,535 193.5%  

Share Holding

Indian Promoters % 48.3 32.3 149.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 4.6 150.0%  
FIIs % 34.4 3.3 1,042.4%  
ADR/GDR % 0.0 4.6 -  
Free float % 10.5 55.3 19.0%  
Shareholders   56,727 84,811 66.9%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   VENUS REMEDIES  PROCTER & GAMBLE HEALTH  NOVARTIS  J.B.CHEMICALS  SHASUN PHARMA  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 93 Points Higher; Oil & Gas and Realty Stocks Witness Buying(Closing)

Indian share markets traded on a volatile note throughout the day and ended marginally higher. Sectoral indices ended on a mixed note with stocks in the oil & gas sector.

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Oct 16, 2019 03:37 PM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS